<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153903</url>
  </required_header>
  <id_info>
    <org_study_id>4-2019-0476</org_study_id>
    <nct_id>NCT04153903</nct_id>
  </id_info>
  <brief_title>Integrated Coronary Multicenter Imaging Registry - Extended</brief_title>
  <official_title>Integrated Coronary Multicenter Imaging Registry - Extended</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronary images of invasive angiography and optical coherence tomography (or Coronary CT
      angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70%
      stenosis) will be prospectively registered.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of computed FFR derived by coronary images and real FFR values</measure>
    <time_frame>at registration</time_frame>
    <description>FFR values computed by OCT/CT/invasive coronary angiography will be compared by real invasive FFR values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event (Death, acute myocardial infarction)</measure>
    <time_frame>2 years after registration</time_frame>
    <description>Death and occurrence of myocardial infarction during follow-up period will be assessed.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Patients with intermediate lesions</arm_group_label>
    <description>Imaging cohort will be performed invasive angiography and optical coherence tomography (or Coronary CT angiography) with FFR(Fractional Flow Reserve) values of the intermediate lesions (50-70% stenosis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OCT, coronary angiography, FFR</intervention_name>
    <description>Coronary images by OCT and angiography and FFR values will be registered.</description>
    <arm_group_label>Patients with intermediate lesions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Coronary artery disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who underwent coronary CT angiography because of chest pain

          2. Patients who need OCT or FFR evaluation because of intermediate lesions according to
             invasive angiography (diameter stenosis of 50-70%)

          3. Age: 20-80 yrs

          4. Patients who consent and fully understand the protocol

          5. Patients who consent the clinical follow-up

          6. Patients who can be followed-up

        Exclusion Criteria:

          1. Patients who had contrast allergy

          2. Patients who had unstable blood pressure needing the vasopressors

          3. Patients who had severe left ventricular function (left ventricular ejection
             fraction&lt;30%)

          4. Chronic kidney disease who had Cr level of greater than 2.0 mg/dl

          5. Patients whose expected survival is less than 12 months

          6. Patients who had a severe valvular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Cardiovascular Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>November 3, 2019</last_update_submitted>
  <last_update_submitted_qc>November 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

